Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Affective Neuroscience Laboratory Massachusetts General Hospital |
---|---|
Information provided by: | Affective Neuroscience Laboratory |
ClinicalTrials.gov Identifier: | NCT00205946 |
The purpose of the study is to evaluate the effects of a single-dose of Wellbutrin XL (bupropion hydrochloride) on reward processing.
Condition | Intervention | Phase |
---|---|---|
Major Depressive Disorder |
Drug: Bupropion Drug: Placebo |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Crossover Assignment |
Official Title: | The Effects of Acute Administration of Bupropion on Neural Substrates Underlying Hedonic Capacity |
Enrollment: | 32 |
Study Start Date: | April 2005 |
Study Completion Date: | July 2007 |
Arms | Assigned Interventions |
---|---|
Placebo: Placebo Comparator |
Drug: Placebo
Administered 5 hours prior to fMRI scanning (randomly assigned, double blind)
|
Bupropion: Active Comparator |
Drug: Bupropion
150 mg of bupropion administered 5 hours before fMRI scanning
|
A cardinal feature of Major Depressive Disorder is anhedonia, which is a lack of pleasure in normally enjoyable activities. In order to understand reward processing in depressed individuals it is also necessary to study reward processing in people who are not depressed. Bupropion, the active drug in the anti-depressant Wellbutrin XL, has been shown to increase brain reward functioning in animals. The goal of the present study is to investigate the effects of Wellbutrin XL administered to psychiatrically healthy individuals as they perform a computer task known to assess reward processing.
Ages Eligible for Study: | 18 Years to 64 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Concomitant medications other than those listed in the exclusion criteria will be considered on an individual basis. Oral contraceptives will be allowed.
United States, Massachusetts | |
The Depression Clinical and Research Program, Massachusetts General Hospital | |
Boston, Massachusetts, United States, 02114 | |
Affective Neuroscience Laboratory, Department of Psychology, Harvard University | |
Cambridge, Massachusetts, United States, 02138 |
Principal Investigator: | Diego A Pizzagalli, PhD | Harvard University |
Responsible Party: | Harvard University ( Diego Pizzagalli, Principal Investigator ) |
Study ID Numbers: | 2004-P-002234-1, 2004-P002234-1 |
Study First Received: | September 13, 2005 |
Last Updated: | December 4, 2007 |
ClinicalTrials.gov Identifier: | NCT00205946 |
Health Authority: | United States: Federal Government |
Reward Processing Wellbutrin Bupropion |
Dopamine Depression Mental Disorders Bupropion |
Mood Disorders Depressive Disorder, Major Depressive Disorder Behavioral Symptoms |
Dopamine Uptake Inhibitors Neurotransmitter Uptake Inhibitors Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Therapeutic Uses Physiological Effects of Drugs |
Psychotropic Drugs Dopamine Agents Antidepressive Agents, Second-Generation Central Nervous System Agents Pharmacologic Actions Antidepressive Agents |